47N0 Stock Overview A biopharmaceutical company, focuses on the development and commercialization of critical care products. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Citius Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Citius Pharmaceuticals Historical stock prices Current Share Price US$3.29 52 Week High US$20.64 52 Week Low US$3.00 Beta 1.36 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change -90.80% 5 Year Change n/a Change since IPO -85.95%
Recent News & Updates
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval Nov 26 Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $3 million. Nov 19
Forecast breakeven date pushed back to 2026 Nov 18
Nasdaq Hearings Panel Grants Citius Pharmaceuticals' Request to Continue its Listing on The Nasdaq Capital Market to Regain Compliance with the Bid Price Rule on or before December 3, 2024 Nov 14
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (Keytruda®) and Lymphir™ in Cancer Patients with Recurrent Solid Tumors Nov 12
Citius Pharmaceuticals, Inc. Provides Non-Compliance Update Sep 12 See more updates
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval Nov 26 Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $3 million. Nov 19
Forecast breakeven date pushed back to 2026 Nov 18
Nasdaq Hearings Panel Grants Citius Pharmaceuticals' Request to Continue its Listing on The Nasdaq Capital Market to Regain Compliance with the Bid Price Rule on or before December 3, 2024 Nov 14
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (Keytruda®) and Lymphir™ in Cancer Patients with Recurrent Solid Tumors Nov 12
Citius Pharmaceuticals, Inc. Provides Non-Compliance Update Sep 12 Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Aug 13
Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma Aug 08
New minor risk - Market cap size Jul 02
Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution May 22 Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million. May 01
Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma Apr 11
The Nasdaq Stock Market LLC Grants Citius Pharmaceuticals' Request for an Extension through September 9, 2024 to Evidence Compliance with the Bid Price Rule Pursuant to Nasdaq Listing Rule 5550(a)(2) Mar 14
Forecast breakeven date pushed back to 2026 Feb 23
Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir Feb 14
New minor risk - Market cap size Feb 01
Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024 Jan 24
New major risk - Financial position Jan 17
Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters Jan 02
Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor Nov 01
Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee Sep 26
Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market Sep 16
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR Sep 09
Citius Pharmaceuticals, Inc. Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial Aug 11
Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma Jul 30
Citius Pharmaceuticals, Inc. Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids Jun 21
Forecast breakeven date pushed back to 2025 Apr 26
Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors Feb 08
Insufficient new directors Jan 10
Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023 Dec 23
Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma Dec 02
Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma Sep 29
Insufficient new directors Sep 06
Insufficient new directors Jul 13
Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma Jul 13
Insufficient new directors May 18
Citius Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Study of Halo-Lido for the Prescription Treatment of Hemorrhoids Apr 27 Citius Pharmaceuticals, Inc. Announces Executive Changes
Forecast breakeven date pushed back to 2024 Apr 08
Insufficient new directors Apr 07
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/Ontak (E7777) Apr 07
Insufficient new directors Mar 16
Insufficient new directors Feb 17
Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids Feb 16
Citius Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma Dec 07
Forecast to breakeven in 2024 Dec 06
Insufficient new directors Dec 06
Insufficient new directors Nov 03
Insufficient new directors Sep 28
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications Sep 08
Citius Pharmaceuticals, Inc. (NasdaqCM:CTXR) agreed to acquire Rights and Certain Related Assets of Dr. Reddy's Laboratories Limited (BSE:500124) for approximately $150 million. Sep 06
Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned Jul 03
Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial Jun 09
Citius Pharmaceuticals, Inc. Reports Strong Clinical Community Engagement During Mino-Lok Phase 3 Trial-Related Webinar Apr 30
Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $76.500002 million. Feb 20
New 90-day high: €1.69 Feb 20
Citius Pharmaceuticals to Present Update on Mino-Lok and Other Therapies At the Virtual Investor Conferences Small and Microcap Showcase on February 4 Feb 03
Citius Pharmaceuticals, Inc. announced that it has received $20.000012 million in funding Jan 28
Citius Pharmaceuticals, Inc. announced that it expects to receive $20.000012 million in funding Jan 26
New 90-day high: €1.01 Jan 20
Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 09, 2021 Dec 23
Citius Pharmaceuticals, Inc.'s Mino-Lok Trial Sites Resupplied with Registration Batch Product Oct 03
Citius Pharmaceuticals Reports Positive Results from Recent Data Monitoring Committee Meeting for Mino-Lok Phase 3 Trial Sep 30
New 90-day low - €0.72 Sep 02
Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $8.363044 million. Aug 07
New 90-day high - €1.29 Jul 21
Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Jul 17 Shareholder Returns 47N0 DE Pharmaceuticals DE Market 7D 0% -0.3% -0.2% 1Y n/a -17.0% 7.0%
See full shareholder returns
Return vs Market: Insufficient data to determine how 47N0 performed against the German Market .
Price Volatility Is 47N0's price volatile compared to industry and market? 47N0 volatility 47N0 Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 47N0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 47N0's volatility change over the past year.
About the Company Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
Show more Citius Pharmaceuticals, Inc. Fundamentals Summary How do Citius Pharmaceuticals's earnings and revenue compare to its market cap? 47N0 fundamental statistics Market cap €24.51m Earnings (TTM ) -€38.11m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 47N0 income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$39.77m Earnings -US$39.77m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 22:48 End of Day Share Price 2024/11/25 00:00 Earnings 2024/06/30 Annual Earnings 2023/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Citius Pharmaceuticals, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason Kolbert D. Boral Capital LLC. Jason Kolbert H.C. Wainwright & Co. Vernon Bernardino H.C. Wainwright & Co.
Show 1 more analysts 
